The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B- cell lines: Induction of bystander killing in vitro and in vivo

Cancer Gene Therapy

Volumn 7, Issue 1, 2000, Pages 97-106

  Westphal, Eva Maria ^a   Ge, Jiqian ^a   Catchpole, Jan R ^b   Ford, Martin ^b   Kenney, Shannon C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

CB1954; Epstein Barr virus; Gene therapy; Lymphoma; Nitroreductase; Suicide gene

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ALKYLATING AGENT; CYTOSINE DEAMINASE; FLUCYTOSINE; NITROREDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DNA CROSS LINKING; DNA TRANSFECTION; DRUG SENSITIZATION; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TREATMENT OUTCOME;

ANIMALIA; HUMAN HERPESVIRUS 4;

EID: 0033981131     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700102     Document Type: Article

References (38)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields B, Knipe D, Howley P, eds. Fields Virology, 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996:2343-2396.
2. Hamilton-Dutoit SJ, Rea D, Raphael M, et al. Epstein-Barr virus latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Am J Pathol. 1993;143:1072-1085.
3. Hamilton-Dutoit SJ, Audouin R, Diebold J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER1) in AIDS-related lymphomas: correlation with tumor morphology and primary site. Blood. 1993;82:619-624.
4. MacMahon EME, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991;338:969-973.
5. Zur Hausen H, Schulte-Holthauzen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature. 1970;228:1956-1958.
6. Weiss L, Mohaved L, Warnke R, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989;320:502-506.
7. Shibata D, Weiss L. Epstein-Barr virus-associated gastric carcinoma. Am J Pathol. 1992;140:769-774.
8. Lee E, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth muscle cell tumors occurring after organ transplantation. N Engl J Med. 1995;332: 19-25.
9. McClain K, Leach C, Jenson H, et al. Association of Epstein-Barr virus with leiomyosarcoma in children with AIDS. NEJM. 1995;332:12-18.
10. Rogers R, Ge J, Holley-Guthrie E, et al. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther. 1996;7: 2235-2245.
11. Kenney S, Ge J, Westphal EM, et al. Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Hum Gene Ther. 1998;9:1131-1141.
12. Franken M, Estabrooks A, Cavacni L, et al. Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Nat Med. 1996;2:1379-1382.
13. Judde JG, Spangler G, Magrath I, et al. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum Gene Ther. 1996;7:647-653.
14. Mucke S, Polack A, Pawlita M, et al. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells. Gene Ther. 1997;4: 82-92.
15. Langle-Rouault F, Patzel F, Benavente A, et al. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA-1: implications of the nuclear import of plasmids. J Virol 1998;72:6181-6185.
16. Freeman SM, Aboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
17. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
18. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46: 5276-5281.
19. Bi W, Parysek L, Warnick R, et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
20. Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol. 1994;56:203-209.
21. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 1994;91:8302-8306.
22. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA. 1992;89:33-37.
23. Connors TA. The choice of prodrugs for gene-directed enzyme prodrug therapy of cancer. Gene Ther. 1995;2:702-709.
24. Bridgewater JA, Springer CJ, Knox RJ, et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer. 1995;31A:2362-2370.
25. Knox RJ, Friedlos F, Boland MP. The bioactivation of CB1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev. 1993;12:195-212.
26. Green NK, Youngs DJ, Neoptolemos JP, et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the Escherichia coli nitroreductase gene. Cancer Gene Ther. 1997;4: 229-238.
27. Clark AJ, Iwobi M, Cui W, et al. Selective cell ablation in transgenic mice expressing E. coli nitroreductase. Gene Ther. 1997;4:101-110.
28. Drabek D, Guy J, Craig R, et al. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 1997; 4:93-100.
29. Bridgewater JA, Knox RJ, Pitts JD, et al. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther. 1997;8:709-717.
30. Knox RJ, Boland MP, Friedlos F, et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone). Biochem Pharmacol. 1988;37:4671-4677.
31. Lawrence TS, Rehemtulla A, Ng EY et al. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res. 1998;58:2588-2593.
32. Venitt S, Crofton-Sleigh C. The toxicity and mutagenicity of the anti-tumor drug 5-aziridino-2,4-dinitrobenzamide (CB1954) is greatly reduced in a nitroreductase-deficient strain of E. coli. Mutagenesis. 1987;2:375-381.
33. McNeish IA, Green NK, Gilligan MG, et al. Virus-directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 1998;5:1061-1065.
34. Wei MX, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther. 1994;5:969-978.
35. Wei MX, Tamiya T, Rhee RJ, et al. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1995;1:1171-1177.
36. Kojima A, Hackett NR, Ohwada A, et al. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest. 1998;101:1789-1796.
37. Danks MK, Morton CL, Pawlik CA, et al. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res. 1998;58:20-22.
38. Rainov NG, Dobberstein KU, Sena-Esteves M, et al. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther. 1998;9:1261-1273.